Chronic Myeloid Leukemia Highlights From SOHO 2020

Ehab Atallah, MD


October 02, 2020

Dr Ehab Atallah, from the Medical College of Wisconsin in Milwaukee, discusses key poster presentations on chronic myeloid leukemia (CML) from the Society of Hematologic Oncology (SOHO) 2020 virtual meeting.

Dr Atallah reports on the ENESTnd study, which indicated that gene signatures could determine which patients would be good responders to tyrosine kinase inhibitors (TKIs).

He also discusses a trial supporting the use of lower doses of TKIs, which showed a 96% complete response rate and fewer side effects using 50 mg vs 100 mg of dasatinib.

Next, Dr Atallah discusses the OPTIC trial, which aimed to define optimal dosing of ponatinib. Patients were randomly assigned to either 45, 35, or 15 mg daily. The lower starting doses proved efficacious in most patients, but those with a T315I mutation responded best to the highest dose.

Dr Atallah next highlights early data on asciminib, a promising new third-line TKI that showed a major molecular response of 77% in patients with chronic-phase CML.

Finally, Dr Atallah discusses a study that found discrepancies between guideline recommendations for stopping TKI treatment and oncologist practice patterns regarding this important option.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.